Soluplus(®) based 9-nitrocamptothecin solid dispersion for peroral administration: preparation, characterization, in vitro and in vivo evaluation

Int J Pharm. 2014 Dec 30;477(1-2):399-407. doi: 10.1016/j.ijpharm.2014.10.055. Epub 2014 Oct 29.

Abstract

Our study aimed to develop an amorphous 9-nitrocamptothecin solid dispersion (9-NC-SD) using polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus(®)) for improving its oral bioavailability and antitumor efficacy in vivo. Freeze-dried 9-NC-SD with an optimized drug/polymer ratio at 1:15 (w/w) was characterized by powder X-ray diffraction, scanning electron microscopy and Fourier transform infrared spectroscopy. The amorphous form of 9-NC was obtained by freeze-drying and the aqueous solubility of 9-NC was increased to 1.42 mg/mL. Upon dilution, 9-NC-SD was proven to form micellar structures with an average size distribution around 58 nm ± 5 nm (PDI=0.107 ± 0.016). Moreover, 9-NC-SD showed significantly increased intracellular uptake efficiency in Caco-2 cells compared to free 9-NC. Furthermore, the AUC0-8h of 9-NC-SD following oral administration showed a 2.68-fold increase in the lactone form of 9-NC compared to that of free 9-NC in Sprague-Dawley rats. The 9-NC-SD did not show obvious inflammatory responses and gastrointestinal toxicity following oral administration as demonstrated by the histological analysis of the rat intestinal sections. Thus, 9-NC-SD represents a promising approach for improving the solubility and oral bioavailability of drugs with poor solubility.

Keywords: 9-Nitrocamptothecin; Antitumor effect; Oral bioavailability; Solid dispersion; Soluplus(®).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Agents / toxicity
  • Biological Transport
  • Caco-2 Cells
  • Camptothecin / administration & dosage
  • Camptothecin / analogs & derivatives*
  • Camptothecin / pharmacokinetics
  • Camptothecin / therapeutic use
  • Camptothecin / toxicity
  • Cell Culture Techniques
  • Drug Carriers / chemistry*
  • Drug Compounding
  • Endocytosis
  • Gastrointestinal Tract / drug effects
  • Gastrointestinal Tract / pathology
  • Humans
  • Male
  • Mice, Inbred ICR
  • Molecular Structure
  • Particle Size
  • Polyethylene Glycols / chemistry*
  • Polyvinyls / chemistry*
  • Rats, Sprague-Dawley
  • Sarcoma 180 / drug therapy
  • Surface Properties

Substances

  • Antineoplastic Agents
  • Drug Carriers
  • Polyvinyls
  • polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer
  • Polyethylene Glycols
  • rubitecan
  • Camptothecin